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Abstract: Medical research is changing into direction of precision therapy, thus, sophisticated
preclinical models are urgently needed. In human pathogenic virus research, the major technical
hurdle is not only to translate discoveries from animals to treatments of humans, but also to overcome
the problem of interspecies differences with regard to productive infections and comparable disease
development. Transgenic mice provide a basis for research of disease pathogenesis after infection
with human-specific viruses. Today, humanized mice can be found at the very heart of this forefront
of medical research allowing for recapitulation of disease pathogenesis and drug mechanisms in
humans. This review discusses progress in the development and use of transgenic mice for the study
of virus-induced human diseases towards identification of new drug innovations to treat and control
human pathogenic infectious diseases.
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1. Introduction
In times of a global pandemic, it is more obvious than ever that human pathogenic viruses are
a major threat to global health. The emergence of human pathogenic viruses such as SARS-CoV-2
(severe acute respiratory syndrome coronavirus 2) or Zika virus highlights the urgent need of
representative preclinical models to study virus entry, replication and spread within an organism as
tools to develop efficient antiviral therapies and vaccinations. Aside from that, also several well-known
human pathogenic viruses that are characterized in molecular detail like influenza virus, human
immunodeficiency virus (HIV) or hepatitis viruses still remain a huge threat to public health.
Mechanisms of infection, replication and disease pathology differ widely among different viruses.
Suitability of cell culture systems or organoids to obtain comprehensive knowledge about viral
characteristics or to test antiviral approaches is highly limited due to the lack of a functional immune
system and vasculature. Thus, animal models still represent a unique opportunity to study viral
replication processes and antiviral agents in vivo. Rodent models, and especially mice, are widely
accepted and the preferred preclinical systems as they are readily available and exhibit low maintenance
costs. However, viruses coevolve with their host organisms and, thus, often show a restricted species
specificity frequently complicating the research of human pathogenic viruses in mouse models.
This narrow host range is often based on the lack of surface entry receptors necessary for virus infection
or due to remarkable differences in murine and human innate immune responses upon viral infection.
Accompanying this, tissue tropism of human pathogenic viruses can differ significantly in mice
causing differences in virus-induced pathology (Figure 1). Hence, mouse models often demonstrate
limited susceptibility or permissiveness and, thus, results obtained from studies in murine models
cannot necessarily be extrapolated to humans, which particularly complicates the validity of drug
development and vaccination studies.
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Figure 1. Reasons underlying restricted species specificity of human pathogenic viruses and solutions
provided by the use of transgenic and humanized mouse models. Schematic overview of limitations in
the use of mouse models for research of human pathogenic viruses (left) and examples of different
transgenic/humanized mouse models providing solutions to overcome the respective restrictions (right).
Associated boxes (limitations/solutions) are indicated by the use of the same color. MV: Measles virus;
PV: Poliovirus; HIV: Human immunodeficiency virus; IAV: Influenza A virus; HBV: Hepatitis B virus;
HCV: Hepatitis C virus.
Genetically modified and transgenic mouse models represent a sophisticated possibility to
overcome interspecies differences in human pathogenic virus research such as species specificity and
tissue tropism, allowing to investigate the function of specific human entry receptors, host factors
or innate and adaptive immune responses in immunocompetent organisms. These models were of
significant importance for scientific progress within the last decades and provided immeasurable
insights into virus biology and disease pathogenesis. A decisive milestone was the development of
immune system or tissue-humanized mouse models facilitating infection and replication of human
pathogenic viruses in a humanized system. With recent advances in human cell or tissue engraftment in
transgenic humanized mice, antiviral strategies and vaccines against many human pathogenic viruses
already have been or will be evaluated in the future, towards identification of new drug innovations to
treat and control human pathogenic infectious diseases.
This review aims to provide an overview of different options to genetically engineer and humanize
mice. We will discuss several examples of human pathogenic viruses that have been studied in
translational, human-relevant preclinical systems (see Table 1).
2. Transgenic Mice Expressing Viral Genes
Due to the absence of permissive mouse models for several human viruses, transgenic mouse
strains were developed incorporating essential individual viral genes or even whole virus genomes
within their own genome to investigate virus pathogenicity and characterize specific properties of
viral genes.
Some of the most intensively studied transgenic mouse models expressing viral genomes have been
generated to analyze hepatitis B and C virus (HBV, HCV)-induced liver pathology and virus replication.
Hepatitis B and C infection share a common phenotype of liver pathology induced by chronic
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necroinflammation resulting in liver cirrhosis and hepatocellular carcinoma (HCC). HBV cccDNA
(covalently closed circular DNA) persists in infected host cells and the virus can uniquely integrate its
genome into the DNA of the infected cell. Most integration events retain the HBx antigen [1]. In sharp
contrast, HCV is a positive-strand RNA virus that replicates through a negative-stranded intermediate
in the cytoplasm. Persistence of HCV is thus facilitated by RNA intermediates that remain in infected
host cells. Since murine hepatocytes do not express HBV- and HCV-specific receptors, intrahepatic
infection and virus spread cannot be analyzed in wild type mice [2,3].
In order to study the role of individual HBV genes in the development of hepatopathology,
immunotolerant HBV-transgenic mice were generated by germline modifications. While the expression
of the viral envelope protein did not induce hepatocellular cytopathology, adoptive transfer of
virus–antigen primed splenocytes resulted in hepatocellular injury and immunopathology caused by
MHC I-restricted antigen-presentation to CD8+ T lymphocytes and envelope-specific antibodies [4].
These data provided the first hints for virus-induced immunopathology based on adaptive immune
responses directed against hepatocytes expressing viral genes. Many transgenic lineages that express
individual HBV genes such as the envelope [5–7], core [8], precore [9] and X [10,11] genes under the
control of HBV- or murine liver-specific promoters have been described in the last decades. This led to
substantial improvement in understanding the properties of the respective viral genes. Afterwards,
transgenic mouse models were generated expressing the full viral replicon, which resulted in high-yield
HBV replication in murine kidneys and liver [12]. Using these HBV transgenic mice, efficacy of
antiviral agents such as HBV-specific inhibitors, small interfering RNAs (siRNAs), and cytokines have
been tested [13–16]. Other transgenic mice, induced by microinjection of viral persistence-inducing
replication intermediate cccDNA [17,18] or by adeno-associated virus in vivo transduction of the
HBV replicon, were used to study antiviral agents or vaccination approaches for acute or chronic
infections [19,20]. More recent approaches used HBV transgenic mice to investigate the therapeutic
potential of CRISPR/Cas9 techniques for use in chronic HBV gene therapy [21,22].
Several groups have generated transgenic mice expressing individual HCV proteins or viral
polyproteins to study the effect on liver pathology, steatosis and HCC manifestations [23–29]. However,
since the overexpression of HCV proteins in these transgenic mice differs compared to low level
expression during natural infection, it is unclear whether the obtained findings are transferable to
the pathology observed in humans [30]. Along that line, it was shown that inflammation-associated
hepatocarcinogenesis depends on the host genetic background of the respective transgenic mouse
model [31]. Thus, these models helped to elucidate the pathophysiology of HCV gene products,
but they are limited by their inability to support HCV replication based on the lack of negative-stranded
RNA expression. Compared to transgenic mouse models for HBV, expression of the HCV genome did
not result in viral progeny production or virus genome replication. Thus, these models do not allow
investigation of antiviral agents or vaccination approaches.
Since murine hepatocytes do not express the respective virus entry receptors for HBV and HCV,
the abovementioned studies did neither allow for virus infection studies nor resemble the whole
infection process via the natural route and virus spread as observed within human tissues [16]. Though
limited in their applicability for virus infection studies, these models were groundbreaking for initial
hepatotropic virus research related to the mechanisms of HBV and HCV pathogenesis.
In line with HBV and HCVtg mice, several attempts have been made to generate HIVtg mice
resulting in substantial understanding of virus–host interactions and clinical manifestation of acquired
immune deficiency syndrome (AIDS) symptoms or the development of Kaposi’s sarcoma [32–36].
However, HIVtg mice showed discrepancies in tissue- and immunopathology (reviewed in [37]).
Along that line, mice do neither express respective entry receptors nor the co-factors needed for efficient
viral replication, and, thus, do not allow analyses of virus replication, antiviral strategies or vaccination
approaches [38].
Further examples of transgenic mouse models expressing HBV, HCV or HIV transgenes can be
found in Table 1.
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Table 1. Overview of transgenic mouse models used to study infections by a selection of human pathogenic viruses. This table can only give an overview and makes
no claim to completeness.
Virus Entry Receptors Virus GenomeTransgenic Mice
Entry Receptor
Transgenic Mice
Transgenic Mice with Changes in
Host Factor Expression
Transgenic Tissue/Immune System
Humanized Mice
HIV CD4, CCR5, CXCR4
vHIVwttg [32–34]
vHIVtattg [35–41]
HIVneftg [42–49]
HIVdelgag/poltg [50]
HIVdelgag/pol/envtg [51]
hCD4/hCCR5 [52,53] hCD4/hCCR5/ hcyclin T1 [54]CCR5-/-/HIVgp120tg [55]
MISTRG [56]
DRAG [57]
NOG-EXL [58]
Polio PVR/CD155 hPVR [59–64] hPVR/IFNAR−/− [65]
Measles CD46, CD150, Nectin-4
hCD46 [66,67]
hCD150 [68,69]
hCD46/hCD150 [70]
hCD46/IFNAR−/− [71,72]
HCV CD81, Occludin, CLDN1;CARB1
vHCVNS3/4Atg [23]
vHCVcore,E1,E2tg [24]
vHCVE1,E2tg [25]
vHCVFL-Ntg, vHCVS-Ntg [27]
vHCVcoretg [29]
hCD81/hOccludin [73–75] AFC8-hu-HSC/Hep [76,77]MUP-uPA [78]
HBV NTCP
vHBVtg [6,12,79,80]
vHBVenvelopetg [4]
vHBVdelcoretg [5]
vHBVcoretg [8]
vHBVHBeAgtg [9]
vHBVHBsAg,pre-S,Xtg [7]
vHBVHBxtg [10,11]
vHBVHBstg [81]
vHBVpreS/Stg [82]
vHBVtg/HNF1−/− [83]
vHBVHBstg/Abcb4−/− [84]
A2/NSG—hu HSC/Hep [85]
MUP-uPA [78,86,87]
SARS-CoV-2 ACE-2, TMPRSS2 hACE2 [88–92]
Influenza S,3-/2,6-sialic acid residues
hMxA [93]
hHLA-A2 [94,95]
hHLA-DR3 [96]
DRAGA [97]
Dengue Heparan sulfate, DC-SIGN/L-SIGN,mannose receptor, laminin receptor
hTNFα [98]
hHLA-A, B [99]
IFNAR−/−/HLA-A, B,
DRB1 [100,101]
NSG-A2 [102]
NSG-SGM3 [103]
Ebola
Different attaching factors, i.e., C-type lectins,
T-cell immunoglobulin and mucin domain 1,
tyrosine kinase receptor Axl, Niemann-Pick C1
HLA-DR3 [104]
HLA-A11/DR1 [105]
HLA-A2 [106]
NSG-A2 [107,108]
NSG-SGM3 [109,110]
Zika GlycosaminoglycansNCAM1
hSTAT2 [111]
IFNAR−/−/HLA-B, A,
DRB1 [101,112,113]
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3. Human Cell Surface Receptor Supplemented Mice
Human pathogenic virus’ species specificity and tissue tropism is often a result of host-specific
unique expression patterns of cell surface receptors needed for virus entry. Due to genetic differences
of humans and mice, genes encoding necessary cell surface receptors can be lacking or significantly
differ in mice. This often results in decreased susceptibility of mice for human pathogenic viruses.
This drawback can be overcome by transgenic mice expressing humanized virus entry receptors as a
result of genetic modification.
The current SARS-CoV-2 pandemic is an excellent example of the urgent need of susceptible mouse
models for emerging human pathogenic viruses to gain insights into virus biology and to develop
antiviral strategies and vaccinations. Earlier studies suggested angiotensin-converting enzyme 2 (ACE2)
as essential entry receptor for SARS-CoV viruses [114]. Sequence alignment of human and murine
ACE2 revealed changes in five out of eight amino acids relevant for SARS-CoV-2 spike (S) protein
binding resulting in poor infection efficiency in mice. Transgenic mice expressing the human ACE2 gene
under a human cytokeratin 18 (K18) promoter in the epithelium of lung, colon, liver, and kidneys [88]
were originally generated to study SARS-CoV infections and pathology. These transgenic mice were
amongst the first tested as suitable animal model for SARS-CoV-2 infections, resulting in high virus
infection levels, viral spread to other organs, decline in pulmonary function and lethality of infected
mice. Thus, virus-induced pathology shared many features with human COVID-19 disease [89,90].
Others generated transgenic humanized ACE2 mice by either microinjection of the hACE gene under the
murine ACE2 promoter [91] or by using CRISPR/Cas9 knock-in technology, replacing the endogenous
murine ACE2 with the human ACE2 [92]. These transgenic mouse models are supposed to exhibit the
most natural expression pattern and tissue expression profile of ACE2.
Recently, studies demonstrated interaction of ACE2 with the transmembrane protease/serine
subfamily member 2 (TMPRSS2) which proteolytically cleaves ACE2 and the viral S protein.
This interaction seems to be essential for viral infection efficiency [115]. Thus, recent studies suggest
approaches to create SARS-CoV-2-sensitive transgenic mice based on hACE2 and hTMPRSS2 under the
murine TMPRSS2 promoter in epithelial cells by applying CRISPR/Cas9 technology [115].
Another successful and well-studied example of how to facilitate infection of nonpermissive mice
with human pathogenic viruses, is the generation of transgenic mice expressing the human entry
receptors for poliovirus (PV) infection. PVs are highly pathogenic for humans and are known to be
the causative agent of human paralytic poliomyelitis, which is developed in approximately 1% of
infected individuals [116,117]. In humans, PV has a primary tissue tropism for epithelial cells in the
pharyngeal and intestinal mucosa. PV can also infiltrate the central nervous system via the blood
stream and possesses a distinct cell tropism for motor neurons, which are known to highly express the
PV receptor (PVR or CD155) [116,118]. Viral infection necessarily requires surface exposition of human
PVR. Thus, already in the early 90s transgenic mice expressing the human PVR gene were successfully
generated by germline modifications to allow in vivo studies of PV infection and manifestation of
poliomyelitis [59,60]. Transgenic mice are permissive for virus infection via parenteral routes and
demonstrate neuronal histopathology comparable to paralysis in humans. These studies were of great
importance for the analysis of PV neurovirulence and have been used for the investigation of antiviral
approaches. However, the virus does not replicate in the alimentary tracts of hPVR-tg mice after oral
administration, which is the primary route of infection in humans [59–61]. When hPVR was expressed
under the promoter of the murine orthologue Tage4, mice were more susceptible to oral PV infection.
However, only mice of an age of up to three weeks developed symptoms of poliomyelitis even though
these mice were more susceptible to oral infection compared to mice expressing hPVR under the human
promoter [62]. Several other attempts were made to express PVR in the alimentary tract of mice by
expressing PVR under the control of diverse promoters [63,64]. Unfortunately, none of these attempts
resulted in a transgenic mouse model highly susceptible to oral virus infection. These results suggest
that the expression of hPVR in the intestine is not solely responsible for infection establishment and
indicate that other host factors might be involved in efficient viral infection and tissue permissiveness.
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Interestingly, it was shown that PV is not able to interfere with the murine interferon (IFN) system.
Thus, transgenic mice expressing the human PVR and lacking the alpha/beta interferon receptor (IFNAR)
gene were generated [119]. These mice were the first to be susceptible to oral infection and exhibited
efficient viral infection and replication. This study showed that IFN-induced immune responses play
an important role in the infection and multiplication of orally administered PV in the small intestine.
However, uncontrolled PV replication also caused severe lesions in tissues that are not susceptible to
PV infection in immunocompetent humans, nonhuman primates or mice [65]. This is one out of many
examples of how combinations of human transgenes and knockouts in antiviral host genes allows
infection of rodents even though tissue tropism and disease outcome are not necessarily reflecting the
human disease phenotype. Comparable approaches for human receptor-transgenic mice deficient in
IFN-induced immune responses were also applied for studies of other human pathogenic viruses such
as measles viruses (Table 1) [69,70]. Nevertheless, these models primarily only allow for productive
virus infection of mice but do not fully resemble the true mechanisms underlying host permissiveness
and antiviral host processes.
4. Transgenic Integration of Human Host/Immune Response Factors
Not only the expression and presence of surface receptors have a decisive influence on the
permissiveness of mice for human pathogenic viruses. Differences in host determinants and intracellular
antiviral responses also play an important role in the different outcome of virus replication, susceptibility
of the organism to certain viruses as well as disease pathology in mice versus humans.
Several human pathogenic viruses such as influenza A viruses (IAV) have the capability to infect
laboratory inbred strains of mice, such as BALB/c, C57BL/6 or DBA/2j [120]. Amongst the best-studied
mouse-adapted IAV strains are H1N1 A/Puerto Rico/8/34 (PR8) or A/WSN/1933 (WSN). Thus, inbred
mice are per se permissive for various, though not all, influenza viruses, although mice do not belong to
the group of natural hosts of IAV. Within the last decade, mouse models have played a significant role
in understanding pathogenesis and molecular mechanisms underlying IAV infection. Nevertheless,
it was shown that infection selectivity based on individual patterns of 2,3- and 2,6-linked sialic acid
residues, serving as entry receptors for avian and human IAVs respectively, varies in respiratory cell
populations in mice and humans [121,122].
Additionally, depending on the infectious dose given and the strains used, IAV infection shows a
more severe disease phenotype and lethality in mice compared to humans. Studies suggested that
the IFN-regulated Mx gene plays a major role in innate immune responses to control IAV infection.
While the majority of wild type mice express a functional Mx gene and, thus, show resistance to IAV
infection, several inbred mouse strains demonstrate large deletions or nonsense mutations within
the Mx locus [123,124]. Compared to normal inbred mice, genetically engineered mice of the same
background carrying a functional Mx gene survived otherwise lethal doses of 1918 H1N1 pandemic
and avian H5N1 IAV [125] (extensively reviewed in [126,127]). These data evidenced the role of
antiviral host factors including the intracellular IFN system and IFN-induced genes such as Mx in the
restriction and regulation of IAV infections.
However, murine and human antiviral host factors can essentially differ and mice expressing
murine Mx genes do not necessarily reflect human antiviral intracellular immune responses.
These innate restriction factors represent effective species barriers that need to be overcome by
viruses to invade the human host. IAV poses a constant threat to humans since zoonotic viral
transmissions can cause severe disease and may give rise to pandemics. Thus, transgenic mice
expressing the entire human Mx locus could be explicitly used to investigate the role of human MxA as
a restriction factor that must be overcome by zoonotic IAV strains. Interestingly, these mice exhibited a
higher resistance against avian H5 an H7 viruses but were readily susceptible to seasonal human IAVs
of H1N1 or H3N2 origin that already efficiently adapted to the human host [93].
Not only cell intrinsic immune response factors, but also factors involved in cellular innate and
adaptive immune responses are essential for IAV-induced pathology and present a critical component
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of antiviral immunity. Especially the emergence of zoonotic IAV with surface glycoproteins that
are distinct from seasonal human strains pose a risk and demand preclinical systems to investigate
vaccination approaches and their efficacy in humans. Human transgenic mice expressing the human
MHC class I allele HLA-A*0201 [94,95] or the MHC class II allele HLA-DR3 [96] provided substantial
benefit for screening of different vaccine candidates against IAV [94–96]. Furthermore, these transgenic
mouse models paved the way for vaccination studies and analyses of immunogenic virus epitopes
for various other human pathogenic viruses such as Zika or Ebola (Table 1) [128–130]. Despite the
great progress that has been achieved with these transgenic mouse models, specific characteristics of
immune cells and especially interactions between cells of the innate and adaptive immune responses
still largely differ between mice and humans. In particular, activation processes and marker expression
of cells of the immune response as well as the efficacy of antiviral approaches can be insufficient or
fundamentally different in mice compared to humans.
5. Transgenic Immune System Humanized Mouse Models
Humanized mice with functional human cell or tissue engraftment have advanced research in
the field of human pathogenic virus infections. Engraftment of human hematopoietic stem cells
(HSCs) that develop into functional human immune systems even allows the study of bloodborne
virus infections as well as virus-induced immune responses and immunopathology-mediated disease
pathogenesis, bridging the gap between rodent models and the clinics.
Currently, there are few major mouse models used with varying degrees of immunodeficiency
resulting in different levels of graft acceptance and tolerance for human cells (extensively reviewed
in [131,132]). The nonfunctional protein kinase, DNA-activated, catalytic polypeptide (PRKDC) gene,
resulting in severe combined immunodeficiency (scid), or knockout of recombination-activating genes
(RAG) lead to impaired development of T and B cells [133–135]. Combination with mutations at
the interleukin-2 receptor common gamma chain (IL-2rγ) allows for even more efficient human cell
and tissue engraftment due to severe impairments in multiple cytokine complexes and a profound
defect in natural killer (NK) and NKT cell development [136]. Immunodeficiency can be introduced
in different genetic backgrounds, however, use of nonobese diabetic (NOD) mice was shown to
further increase immune tolerance and even resulted in defective macrophage and dendritic cell
(DC) function [137–140]. Most commonly used immunodeficient mice are: NSG (NOD scid gamma),
NRG (NOD Rag gamma) and NOG (NOD scid gamma) mice. The latter contain a IL2rg null
mutation that does not even allow for cytokine binding. There are three conventional ways to engraft
immunodeficient mice with functional human cells: (i) intravenous injection of human bone marrow,
cord blood, or granulocyte-colony-stimulating factor (G-CSF) cytokine-mobilized peripheral blood
mononuclear cells (PBMCs) which are all rich in human HSC activity, leads to the engraftment of a
naive human hemopoietic system in the murine recipient (HSC model) [141,142]. (ii) Engraftment
can be achieved by injection of human PBMC, spleen or lymph node cells into immunodeficient mice
(PBMC or PBL model) [141–144]. (iii) To establish BLT (bone marrow, liver, thymus) humanized
mice, fetal liver and thymus fragments are implanted under the renal capsule in irradiated adult
immunodeficient mice, and HSCs derived from the same fetal liver are injected intravenously [145,146].
Aforementioned humanized mouse models with fully functional human immune responses have
been applied for studies with different human pathogenic viruses. However, although humanized
mice with engrafted human cells provided suitable tools to study human-specific pathogens in the
past, these models have been shown to possess some major drawbacks such as development of
graft versus host disease, the absence of erythrocytes and neutrophils within reconstituted human
immune systems, low numbers and functionally impaired human myeloid cells, dominance of
immature B cells as well as minimal production of antigen-specific IgG class antibodies [146–149].
Many recent advances in this area have addressed these limitations and include the derivation of
mouse strains transgenic for human cytokines or HLA alleles, allowing for enhanced human cell
engraftment and immune responses [148,150]; extensively reviewed in [132]. Most prominent examples
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are for instance: huNOG-EXL mice, immunodeficient NOG mice expressing human GM-CSF and
human IL-3 cytokines to support myeloid lineage engraftment. These animals show higher overall
engraftment levels of human HSCs with higher levels of myeloid cell differentiation [151]. Furthermore,
NSG-SGM3 triple transgenic mice express human IL-3, GM-CSF and stem cell factor (SCF), therefore
combining the features of the highly immunodeficient NSG mouse with the expression of cytokines
that support the stable engraftment of myeloid lineages and regulatory T cell populations [152].
Another example for more efficient human cell engraftment is the MISTRG mouse model. These highly
immunodeficient mice express the human signal-regulatory protein alpha (SIRPα), protecting human cells
from being phagocytosed. Finally, cytokine-encoding genes M-CSF, IL-3, GM-CSF and thrombopoietin
are humanized by knock-in replacement, resulting in defects in mouse cell populations dependent on
the respective mouse cytokine and, thus, support for engraftment of transplanted human cells [153].
NSG-HLA-A2/HHD immunodeficient mice express human HLA class 1 heavy and light chains allowing
for the generation of functional human T cell subsets with HLA-restricted immune responses [154].
DRAG mice are NRG animals with chimeric human-mouse class II transgenes encoding the HLA class
II antigen binding domain molecules (defined by the HLA-DR4 genotype) fused to the I-Ed MHC class
II molecule. The presence of these HLA-DR4-IE transgenes allows enhanced HLA-DR-matched HSC
engraftment and subsequent human T and B cell development [155]. Interestingly, mice coexpressing
HLA-DR4 and HLA-A2 molecules (DRAGA mice) did not differ in their ability to develop human T
and B cells, to reconstitute cytokine-secreting CD4+ T and CD8+ T cells, or to undergo immunoglobulin
class switching [156]. Most recently, HUMAMICE were developed, the only mouse line combining
the knockout of both murine MHC class I and II with subsequent expression of human HLA-A2 and
HLA-DR1 providing a platform for the generation of humanized models that better resist graft versus
host disease [157].
These different humanized transgenic mice are currently in use to model the human immune
system in scenarios of health and pathology, and serve as a basis for the analysis of human pathogenic
viruses, enabling the evaluation of therapeutic candidates in an in vivo setting more relevant to human
physiology, in the future.
6. Transgenic Humanized Mouse Models for Human-Specific Bloodborne and Hepatotropic Viruses
Improvement of humanized mouse models has opened up a new avenue for studying bloodborne
viruses such as HIV as well as hepatitis B and C viruses, where knowledge was previously gained in
viral gene/genome transgenic mice. In addition, hemorrhagic fever-inducing viruses such as dengue
virus (DENV) or Ebola could be finally investigated in vivo by application of the aforementioned
mouse models that allow for human immune system induced pathology.
The most extensively studied virus in transgenic immune system humanized mice is HIV. HIV
research is confronted with various challenges such as the species barrier that was overcome by
engraftment of human fetal thymic or lymph node implants allowing for acute infection. However,
the RNA genome of HIV is reverse-transcribed into DNA and integrated into the host genome,
resulting in latent infections difficult to clear by the host immune system. Additional humanization
and especially the use of BLT mice finally allowed for the modelling of HIV transmission via vaginal
and rectal routes, latency and a dynamic interplay of HIV-specific cellular immunity and viral escape
from immune pressure (reviewed in [158,159]). For instance, HIV-infected MISTRG mice showed
lymphocyte activation and changes in lymphocyte subsets in blood and spleen, recapitulating hallmarks
of HIV infection in humans [56]. Recently, a study demonstrated that intravaginal HIV infection
of DRAG mice, whose mucosal tissues are highly enriched for human lymphocytes expressing the
receptors and cofactors needed for HIV entry and replication, resulted in replication competent viruses
that spread rapidly. Bone marrow, gut, female reproductive tract and lymph nodes as well as plasma
were positively tested for viral RNA. Observation of viral persistence in diverse tissues such as the
bone marrow, lymph nodes, and the brain indicated potential sanctuary sites for HIV to escape the
host immune system [57]. Furthermore, HIV productively replicated in humanized NOG-EXL mice,
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and infection induced a decrease in the percentage of CD4+ T cells, inversion of the CD4:CD8 ratio,
and changes in cell populations, such as monocytes and dendritic cells, that recapitulated the pathology
found in human infection [58].
Preclinical studies on mosquito-borne DENV causing systemic disease have proven to be a
difficult task because the virus demonstrates a tropism for different subsets of human cells [160].
In addition, several clinical isolates of DENV do not replicate or cause pathology in nonhuman hosts.
Nonhuman primate models were of limited use due to the absence of clinical signs of dengue fever,
while mice are naturally resistant against DENV, as the virus is not capable to inhibit murine IFN
signaling. Different knockout and transgenic mouse models have been utilized to investigate different
DENV research questions. However, due to significant drawbacks, these models did not lead to
major breakthroughs in the understanding of human dengue fever. An additional aggravating factor
in research on DENV infection is that previous immunity is considered a major risk factor for the
development of severe hemorrhagic fever and most severe symptoms are observed at the peak of the
human antiviral immune response (reviewed in [161–163]). Thus, humanized mouse models have
become the most common models used for the study of DENV and the rapid development of new
transgenic human–mouse hybrid models recently increased insights into DENV infections. Infection
of humanized mice represented some clinical manifestations also observed in humans such as viremia,
fever, rash, thrombocytopenia, and erythema. However, since pre-existing immunity is a well-known
risk factor for the development of severe dengue disease, it is important that the infection of humanized
animal models results in development of humoral and cellular immune responses as observed in
humans following primary DENV infection. NSG-A2 mice showed efficient viral replication and
IgM antibodies directed against the envelope protein were detected in sera of mice. Furthermore,
splenocytes isolated from DENV-immunized mice showed induction of human DENV-specific T cell
responses evidenced by IFN γ, IL-2, and TNF-α secretion after stimulation with three known HLA
A2-restricted dengue virus-specific CD8 T cell epitopes [102]. When compared with NSG-BLT mice,
transgenic NSG-SGM3-BLT demonstrated per se higher levels of mature naive (resting) B cells and
lower levels of transitional B cells. Consistently, after DENV infection, higher levels of antigen-specific
IgM and IgG were observed, suggesting an enhanced development and maturation of human B cells
that can be used for studies in human antigen-specific B cell responses [103]. However, experiments
published using humanized mouse models for DENV infection have failed to consistently demonstrate
plasma leakage and hemorrhagic phenomenon seen in severe human DENV infection, indicating the
need of additional humanization of the vascular system.
In the past years, human-associated viruses have been extensively studied in mice with humanized
immune systems. Nevertheless, study of hepatotropic pathogens such as hepatitis B and C viruses
remained elusive due to the lack of human hepatocytes in the mouse liver. Human liver chimeric
mice are still the gold standard for allowing hepatotropic infections, even though the highly
immunocompromised status of these engrafted mice precluded liver pathogenesis mediated by
human immune surveillance. Thus, transgenic mice with dual humanization of immune system
and liver were established (reviewed in [164,165]). However, the best animal strains for hepatocyte
transplantation are not optimal for human HSC engraftment, and vice versa. To promote engraftment
of human hepatocytes, transgenic mice expressing a fusion protein of the FK506 binding protein
(FKBP) and caspase 8 under control of the albumin promoter (AFC8), which induces mouse liver cell
death after administration of synthetic drug AP20187, were used. AFC8-hu HSC/Hep mice supported
HCV infection in the liver and generated a human immune T cell response against HCV antigens.
HCV infection induced liver inflammation, hepatitis, and fibrosis, which correlated with activation of
stellate cells and expression of human fibrogenic genes [76,77]. Nevertheless, in this mouse model,
no significant HCV viremia was detected in the blood, a prerequisite in blood borne human infection.
The A2/NSG-hu HSC/Hep mouse, a humanized mouse model with both human immune system
and human liver cells by reconstituting immunodeficient human HLA-A2 transgenic mice with human
hematopoietic stem cells and liver progenitor cells, supported HBV infection and establishment
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of persistent infection. Human immune responses, albeit impaired in the liver, chronic liver
inflammation and liver fibrosis were detected in infected animals. In addition, application of
an HBV neutralizing antibody efficiently inhibited HBV infection and associated liver diseases in
humanized mice. Furthermore, HBV-mediated liver disease was found to be associated with high
levels of infiltrated human macrophages with an M2-like activation phenotype, which has been shown
to be associated with accelerated liver fibrosis and necrosis in patients with acute HBV-induced liver
failure [85].
Although these transgenic humanized mouse models have not been used extensively in research
on human pathogenic viruses yet, their benefit especially in drug and vaccination studies is undeniable.
Interestingly, it already has been shown that DRAGA mice can be used to generate cross-reactive,
human anti-influenza monoclonal antibodies (hu-mAbs). DRAGA mice were found to be suitable
for influenza virus infection, as they can clear a sublethal infection and sustain a lethal infection
with influenza virus. A single administration of viral hemagglutinin protein-specific hu-mAbs in
IAV-infected DRAGA mice significantly delayed lethality by reducing lung damage [97].
7. Conclusions and Future Directions
Successful establishment of transgenic and especially transgenic humanized mice provided
immeasurable opportunities to advance medical research on infectious diseases that were previously
inaccessible. The transgenic mouse models described in this review are, amongst others,
groundbreaking for the understanding of human pathogenic virus infections and their disease pathology.
Along that line, these mouse models provide the possibility to study emerging virus-induced diseases,
as discussed for SARS-CoV-2. Since some viruses have the unique ability to cross species boundaries
and adapt to new hosts, humanized mouse models will continue to play a crucial role in understanding
newly emerging or human-adapting viruses, in the future. However, existing models are still far from
being perfect. A mouse model that can be applied to study all known and newly emerging human
pathogenic viruses while completely mimicking virus-induced disease pathogenesis does not exist and
researchers still need to consider the scientific questions in the respective areas of the disease to select
the best suitable animal model. While virus entry receptor or antiviral host factor humanized mice
are a great model to study virus infection, replication and the role of single human genes involved
in antiviral immune responses, they are not suitable to evaluate disease pathogenesis or efficacy
of antiviral approaches as the complexity of human immune responses is not necessarily reflected.
Especially the analysis of possible vaccination candidates or antiviral approaches additionally requires
immune system humanized mice. Amongst these, HUMAMICE are highly sophisticated humanized
models that allow e.g., to study antigen specificity of human immune cells, however, without additional
humanization, these animals are not susceptible for infection with human pathogenic viruses such
as SARS-CoV-2.
The ideal future model for most human pathogenic virus infections will be an animal model with
a reconstituted human immune system presenting antigens in the human HLA context, constitutively
expressing human cytokines necessary for efficient immune cell development. In addition, specific
human organs or humanized cell types would be needed to mimic viral transmission routes and
disease pathology. Such a model does not exist yet, but with the current advances in technology it
might be only a matter of time to have it available to study human specific virus infection complexity
and to develop more efficient vaccine and treatment strategies. Furthermore, there still is the sustained
need to identify and replace human-specific factors that are absent in mice but are needed for optimal
human cell differentiation and function to decrease or even prevent the development of graft versus
host disease that still occurs in many of the human immune system engrafted models.
Thus, key improvements in specific areas are still required, however, with careful characterization,
the future will yield more appropriate preclinical models, supporting more rapid and relevant
translational drug discovery and development.
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